1 / 36

RESPIRATORY PAEDIATRICS

RESPIRATORY PAEDIATRICS. Dr Pamela Lewis. OBJECTIVES. History – Key points Examination Common respiratory problems in children. The Respiratory History. History of presenting complaint Nature of symptoms Chronic symptoms Risk Factors Associated symptoms Growth Impact.

claudia-dale
Télécharger la présentation

RESPIRATORY PAEDIATRICS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RESPIRATORY PAEDIATRICS Dr Pamela Lewis

  2. OBJECTIVES • History – Key points • Examination • Common respiratory problems in children

  3. The Respiratory History • History of presenting complaint • Nature of symptoms • Chronic symptoms • Risk Factors • Associated symptoms • Growth • Impact

  4. Respiratory Risk Factors • Prematurity • Chronic lung disease • Smoking • Atopy • Family history • Immunodeficiency • Social

  5. Respiratory Examination • Observe • Respiratory rate • Clubbing • HR • Cyanosis • Chest Shape • Expansion • Percussion • Auscultation

  6. Bronchiolitis • Viral infection of the small airways • Respiratory Syncitial Virus • Infants • Symptoms • Signs • Management • Prevention

  7. Bronchiolitis Presentation • Cough, respiratory distress, poor feeding • Tachypnoea, recession, crackles and wheeze • Supportive management: Oxygen, fluids no proven role for bronchodilators or steroids, limited evidence for ribavarin, ventilatory support

  8. Bronchiolitis Prevention • Palivizumab monoclonal antibody, monthly injections to at risk population • Vaccine? Not currently

  9. CROUP • Viral infection of the upper airways • Parainfluenza virus • Presentation • Management

  10. Croup Presentation and Management • Barking cough, respiratory distress poor feeding • Stridor, tracheal tug, recession, not toxic • Limit anxiety and call for assistance if severe • Steroids oral dexamethasone • Consider nebulised adrenaline • Airway support if necessary

  11. Epiglottitis • Severe upper airway infection • Haemophilus influenzae • Presentation • Management • Prevention

  12. Epiglottitis Presentation and Management • Toxic, drooling stridor and respiratory distress • Medical Emergency • Call for HELP • Keep child calm • Rapid Sequence induction of anaesthesia • IV Ceftriaxone • Hib Vaccine

  13. Asthma • Common 1.1 million children in uk receiving treatment for asthma • Inflamatory condition of the bronchial airways resulting in increased mucus production, mucosal swelling and muscle contraction. Reversible

  14. Diagnosis of Asthma in Children • Presence of key features • Assessment of trials of treatment • Repeated reassessment and question diagnosis if not responding • Pulmonary function tests (if age appropriate)

  15. Key Features in Asthma • Symptoms: cough, wheeze, SOB,chest tightness, exertional symptoms • Risk Factors: atopy, FH, smoking, preterm • Signs: None, hyperexpansion, Harrisons sulci

  16. PFT in Diagnosis of asthma • Depends on age • >20% diurnal variation in PEF on >3 days/wk for 2 weeks • FEV1 > 15% after salbutamol • FEV1> 15% drop after 6mins running • Bronchial hyperreactivity

  17. Differential Diagnosis in Asthma • Viral wheezing • GOR • Suppurative lung disease • Congenital structural leision • Immunodeficiency • Cardiac

  18. Primary Prevention • Allergen avoidance • Breast feeding • Microbial exposure • Smoking

  19. Secondary Prevention • Allergen avoidance • House Dust Mite eradication • Smoking • Pollution • Dietary • Homeopathy

  20. British Thoracic Society Management • Aims of treatment Early control maintain control with stepwise approach • Assessment Minimal symptoms day and night No exacerbations No reduction in exercise capability normal lung function

  21. BTS Asthma Management • STEP 1 • Mild intermittent symptoms • Use beta 2 Agonist as required • Move to step 2 if needed >3x/week or night symptoms>1x/week or if exacerbation in last 2 years

  22. BTS Asthma Management • Step 2 • Regular preventer therapy • Inhaled beta 2 agonist prn and regular standard dose inhaled corticosteroid

  23. BTS Asthma Management • Step 3 • Add on Treatment • Beta 2 agonist as required and regular standard dose inhaled corticosteroid and if >5yrs regular long acting beta 2 agonist, if not controlled increase inh steroid dose to top of standard range and if still uncontrolled add in leukotriene antagonist or oral theophyline

  24. BTS Asthma Management • If <5years add leukotriene antagonist

  25. BTS Asthma Management • Step 4 • If under 5yrs child should be refered to a respiratory paediatrician • If >5yrs inhaled beta 2 agonist as needed and high dose inhaled steroids and regular long acting beta 2 agonist and leukotriene antagonist or theophyline

  26. BTS Asthma Management • Step 5 • Refer to respiratory paediatrician • As for step 4 and consider regular steroid tablets or immunosuppressants

  27. Acute AsthmaSeverity Assessment • Mild: cough and wheeze, no distress , able to speak and feed, sats >92% • Moderate: cough, wheeze, use of accessory muscles, sats>92%, feeding, able to speak but breathless.PF>50% if over 5yrs and able to perform • Severe: sats <92%, toobreathless to talk or feed, tachypnoea and use of accessory muscles, tachycardia nb the silent chest

  28. Acute Asthma • Oxygen • Beta 2 Agonist (salbutamol) neb repeat as required • Ipratropium nebs • Steroids prednisolone or iv hydrocortisone • IV salbutamol/ aminophyline • IV magnesium

  29. Drugs in Asthma • Beta 2 Agonists eg salbutamol, terbutaline, can be administered as inhalor or nebulised (BLUE) • Long acting beta 2 agonists inhalors (GREEN) • Steroids inhaled eg beclomethasone (BROWN), Fluticasone(ORANGE). Oral Prednisolone. IV Hydrocortisone • Leukotriene antagonists eg montelukast tablets or sprinkles

  30. CYSTIC FIBROSIS • 7500 cases in uk • 1:25 carrier rate • Autosomal recessive, chromosome 7 • Commonest deletion in UK delta 508 affecting the CFTR protein which codes for chloride channel • Average life expectancy 30-40

  31. CYSTIC FIBROSIS • Multisystem disease • Respiratory; recurrent resp infections with resultant bronchiectasis • GIT; pancreatic insufficiency, meconium ileus equivalent • Hepatic; CF liver disease • Endocrine; diabetes, infertility

  32. CYSTIC FIBROSIS MANAGEMENT • Multidisciplinary team approach • Physiotherapy • Dietetics • Therapeutic • psychological

More Related